<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The oral, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-selective fluoropyrimidine <z:chebi fb="0" ids="31348">capecitabine</z:chebi> represents a major new strategy for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Pooled results from two large, multicentre, open-label, phase III studies comparing oral <z:chebi fb="0" ids="31348">capecitabine</z:chebi> (1250 mg/m2 twice daily for 14 days every 3 weeks) with the Mayo Clinic regimen (<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> [5-FU] 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks) provide information on over 1200 patients receiving first-line chemotherapy for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Analysis of <z:hpo ids='HP_0000001'>all</z:hpo> randomised patients demonstrated a significantly superior overall response rate as assessed by the investigator for <z:chebi fb="0" ids="31348">capecitabine</z:chebi> compared with 5-FU/leucovorin (25.7% versus 16.7%, P&lt;0.0002), reinforcing the individual trial results </plain></SENT>
<SENT sid="3" pm="."><plain>Median time to disease progression, overall survival and duration of response were equivalent in the two treatment groups </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, <z:chebi fb="0" ids="31348">capecitabine</z:chebi> showed a superior safety profile compared with 5-FU/leucovorin, with a significantly lower incidence (P&lt;0.001) of diarrhoea, <z:hpo ids='HP_0010280'>stomatitis</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:hpo ids='HP_0001596'>alopecia</z:hpo>, together with a reduced treatment-related hospitalisation rate </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the incidence of neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo>/<z:hpo ids='HP_0100806'>sepsis</z:hpo> was significantly lower in patients receiving <z:chebi fb="0" ids="31348">capecitabine</z:chebi> </plain></SENT>
</text></document>